Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. Design: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts’ consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. Conclusion: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer.

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer / Vergote I.; Gonzalez-Martin A.; Ray-Coquard I.; Harter P.; Colombo N.; Pujol P.; Lorusso D.; Mirza M.R.; Brasiuniene B.; Madry R.; Brenton J.D.; Ausems M.G.E.M.; Buttner R.; Lambrechts D.; Ausems M.; Brenton J.; Abreu M.; Balboni S.; Banerjee S.; Barberis M.; Barretina Ginesta M.P.; Baurain J.-F.; Bignami M.; Bjorge L.; Blecharz P.; Bruchim I.; Capilna M.; Cerana N.; Cicchetti A.; Collins D.; Concin N.; D'Incalci M.; Davidson B.; de la Motte Rouge T.; De Iaco P.; Demirkiran F.; Denys H.; Doerk T.; Dorum A.; Ferrero A.; Fidalgo A.P.; Genuardi M.; Gladieff L.; Glasspool R.; Grimm C.; Gultekin M.; Hahnen E.; Hasenburg A.; Hegmane A.; Heinzelmann V.; Hogdall E.; Janavicius R.; Jarmalaite S.; Kalachand R.; Kaneva R.; Kilickap S.; Kocian R.; Kolencik D.; Kristeleit R.; Kryzhanivska A.; Leary A.; Lemley B.; Ligtenberg M.; Lopez-Guerrero J.A.; Lord C.J.; Avall-Lundqvist E.; Maenpaa J.; Mahner S.; Marme F.; Marth C.; McNeish I.; Merkelbach-Bruse S.; Mourits M.; Normanno N.; Oaknin A.; Ojamaa K.; Papdimitriou C.; Penault-Llorca F.; Perrone A.M.; Pignata S.; Pikarsky E.; Rouleau E.; Rubio M.; Sapino A.; Schmalfeldt B.; Sehouli J.; Shapira R.; Steffensen K.D.; Sukhin V.; Syrios J.; Szallasi Z.; Taskiran C.; Terzic M.; Tischkowitz M.; Toth I.; Van de Vijver K.; Vardar M.A.; Wasag B.; Wimberger P.; Witteveen E.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 33:3(2022), pp. 276-287. [10.1016/j.annonc.2021.11.013]

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

De Iaco P.;Perrone A. M.;
2022

Abstract

Background: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typically exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi). Current guidelines recommend a range of approaches for genetic testing to identify predictors of sensitivity to PARPi in ovarian cancer and to identify genetic predisposition. Design: To establish a European-wide consensus for genetic testing (including the genetic care pathway), decision making and clinical management of patients with recently diagnosed advanced ovarian cancer, and the validity of biomarkers to predict the effectiveness of PARPi in the first-line setting. The collaborative European experts’ consensus group consisted of a steering committee (n = 14) and contributors (n = 84). A (modified) Delphi process was used to establish consensus statements based on a systematic literature search, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results: A consensus was reached on 34 statements amongst 98 caregivers (including oncologists, pathologists, clinical geneticists, genetic researchers, and patient advocates). The statements concentrated on (i) the value of testing for BRCA1/2 mutations and HRR deficiency testing, including when and whom to test; (ii) the importance of developing new and better HRR deficiency tests; (iii) the importance of germline non-BRCA HRR and mismatch repair gene mutations for predicting familial risk, but not for predicting sensitivity to PARPi, in the first-line setting; (iv) who should be able to inform patients about genetic testing, and what training and education should these caregivers receive. Conclusion: These consensus recommendations, from a multidisciplinary panel of experts from across Europe, provide clear guidance on the use of BRCA and HRR deficiency testing for recently diagnosed patients with advanced ovarian cancer.
2022
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer / Vergote I.; Gonzalez-Martin A.; Ray-Coquard I.; Harter P.; Colombo N.; Pujol P.; Lorusso D.; Mirza M.R.; Brasiuniene B.; Madry R.; Brenton J.D.; Ausems M.G.E.M.; Buttner R.; Lambrechts D.; Ausems M.; Brenton J.; Abreu M.; Balboni S.; Banerjee S.; Barberis M.; Barretina Ginesta M.P.; Baurain J.-F.; Bignami M.; Bjorge L.; Blecharz P.; Bruchim I.; Capilna M.; Cerana N.; Cicchetti A.; Collins D.; Concin N.; D'Incalci M.; Davidson B.; de la Motte Rouge T.; De Iaco P.; Demirkiran F.; Denys H.; Doerk T.; Dorum A.; Ferrero A.; Fidalgo A.P.; Genuardi M.; Gladieff L.; Glasspool R.; Grimm C.; Gultekin M.; Hahnen E.; Hasenburg A.; Hegmane A.; Heinzelmann V.; Hogdall E.; Janavicius R.; Jarmalaite S.; Kalachand R.; Kaneva R.; Kilickap S.; Kocian R.; Kolencik D.; Kristeleit R.; Kryzhanivska A.; Leary A.; Lemley B.; Ligtenberg M.; Lopez-Guerrero J.A.; Lord C.J.; Avall-Lundqvist E.; Maenpaa J.; Mahner S.; Marme F.; Marth C.; McNeish I.; Merkelbach-Bruse S.; Mourits M.; Normanno N.; Oaknin A.; Ojamaa K.; Papdimitriou C.; Penault-Llorca F.; Perrone A.M.; Pignata S.; Pikarsky E.; Rouleau E.; Rubio M.; Sapino A.; Schmalfeldt B.; Sehouli J.; Shapira R.; Steffensen K.D.; Sukhin V.; Syrios J.; Szallasi Z.; Taskiran C.; Terzic M.; Tischkowitz M.; Toth I.; Van de Vijver K.; Vardar M.A.; Wasag B.; Wimberger P.; Witteveen E.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 33:3(2022), pp. 276-287. [10.1016/j.annonc.2021.11.013]
Vergote I.; Gonzalez-Martin A.; Ray-Coquard I.; Harter P.; Colombo N.; Pujol P.; Lorusso D.; Mirza M.R.; Brasiuniene B.; Madry R.; Brenton J.D.; Ausems M.G.E.M.; Buttner R.; Lambrechts D.; Ausems M.; Brenton J.; Abreu M.; Balboni S.; Banerjee S.; Barberis M.; Barretina Ginesta M.P.; Baurain J.-F.; Bignami M.; Bjorge L.; Blecharz P.; Bruchim I.; Capilna M.; Cerana N.; Cicchetti A.; Collins D.; Concin N.; D'Incalci M.; Davidson B.; de la Motte Rouge T.; De Iaco P.; Demirkiran F.; Denys H.; Doerk T.; Dorum A.; Ferrero A.; Fidalgo A.P.; Genuardi M.; Gladieff L.; Glasspool R.; Grimm C.; Gultekin M.; Hahnen E.; Hasenburg A.; Hegmane A.; Heinzelmann V.; Hogdall E.; Janavicius R.; Jarmalaite S.; Kalachand R.; Kaneva R.; Kilickap S.; Kocian R.; Kolencik D.; Kristeleit R.; Kryzhanivska A.; Leary A.; Lemley B.; Ligtenberg M.; Lopez-Guerrero J.A.; Lord C.J.; Avall-Lundqvist E.; Maenpaa J.; Mahner S.; Marme F.; Marth C.; McNeish I.; Merkelbach-Bruse S.; Mourits M.; Normanno N.; Oaknin A.; Ojamaa K.; Papdimitriou C.; Penault-Llorca F.; Perrone A.M.; Pignata S.; Pikarsky E.; Rouleau E.; Rubio M.; Sapino A.; Schmalfeldt B.; Sehouli J.; Shapira R.; Steffensen K.D.; Sukhin V.; Syrios J.; Szallasi Z.; Taskiran C.; Terzic M.; Tischkowitz M.; Toth I.; Van de Vijver K.; Vardar M.A.; Wasag B.; Wimberger P.; Witteveen E.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0923753421048286-main.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 510.84 kB
Formato Adobe PDF
510.84 kB Adobe PDF Visualizza/Apri
ScienceDirect_files_12Apr2023_09-27-45.026.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 430.65 kB
Formato Zip File
430.65 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/863459
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 59
social impact